MX2019014572A - Métodos de ingeniería de carga superficial para la producción de anticuerpos biespecíficos. - Google Patents

Métodos de ingeniería de carga superficial para la producción de anticuerpos biespecíficos.

Info

Publication number
MX2019014572A
MX2019014572A MX2019014572A MX2019014572A MX2019014572A MX 2019014572 A MX2019014572 A MX 2019014572A MX 2019014572 A MX2019014572 A MX 2019014572A MX 2019014572 A MX2019014572 A MX 2019014572A MX 2019014572 A MX2019014572 A MX 2019014572A
Authority
MX
Mexico
Prior art keywords
methods
antibody
bispecific antibody
antibody production
surface charge
Prior art date
Application number
MX2019014572A
Other languages
English (en)
Inventor
Thomas Nesspor
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2019014572A publication Critical patent/MX2019014572A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción se relaciona con métodos para modificar el punto isoeléctrico de un anticuerpo; el método incluye proporcionar un anticuerpo que comprende un primer polipéptido que comprende una región variable de cadena pesada y un segundo polipéptido que comprende una región variable de cadena pesada, y sustituir en al menos uno del primer y el segundo polipéptidos del anticuerpo uno o más residuos de aminoácidos de la región variable de cadena pesada (VH) en las posiciones 7, 9, 11, 14, 41, 70, 74, 82a, 84 y 113, de acuerdo con el sistema de numeración de Kabat, en donde la sustitución aumenta o disminuye el punto isoeléctrico del anticuerpo.
MX2019014572A 2017-06-05 2018-06-04 Métodos de ingeniería de carga superficial para la producción de anticuerpos biespecíficos. MX2019014572A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762515297P 2017-06-05 2017-06-05
PCT/IB2018/053996 WO2018224950A1 (en) 2017-06-05 2018-06-04 Methods of engineering surface charge for bispecific antibody production

Publications (1)

Publication Number Publication Date
MX2019014572A true MX2019014572A (es) 2020-07-29

Family

ID=64566522

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014572A MX2019014572A (es) 2017-06-05 2018-06-04 Métodos de ingeniería de carga superficial para la producción de anticuerpos biespecíficos.

Country Status (10)

Country Link
US (2) US11192951B2 (es)
EP (1) EP3634994A4 (es)
JP (1) JP7268011B2 (es)
KR (2) KR20240056666A (es)
CN (1) CN110959012A (es)
AU (1) AU2018279278A1 (es)
BR (1) BR112019025612A2 (es)
CA (1) CA3065447A1 (es)
MX (1) MX2019014572A (es)
WO (1) WO2018224950A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210126699A (ko) * 2019-02-14 2021-10-20 메뤼스 엔.페. 2개 이상의 항체를 포함하는 조성물의 제조
EP4126929A1 (en) * 2020-03-25 2023-02-08 Eli Lilly and Company Multispecific binding proteins and methods of developing the same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
EP4218801A3 (en) * 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
JP2011530297A (ja) * 2008-08-14 2011-12-22 セファロン・オーストラリア・ピーティーワイ・リミテッド バリアントドメイン抗体
WO2010131733A1 (ja) * 2009-05-15 2010-11-18 中外製薬株式会社 抗axl抗体
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
SG10201800757TA (en) 2010-04-20 2018-02-27 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
MX370848B (es) * 2012-10-04 2020-01-08 Dana Farber Cancer Inst Inc Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso.
TWI693073B (zh) * 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
CA2904337A1 (en) * 2013-03-14 2014-10-02 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
CN107108729A (zh) * 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
JP6725532B2 (ja) * 2015-04-29 2020-07-22 インスティテュート フォー リサーチ イン バイオメディシン 多重特異性抗体によるサイトカインの非常に強力な中和およびその利用
CA2990518A1 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
TW202342532A (zh) 2015-09-18 2023-11-01 日商中外製藥股份有限公司 Il-8結合抗體及其用途
JP6959912B2 (ja) * 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
EP3405492B1 (en) * 2016-01-21 2020-10-21 Novartis AG Multispecific molecules targeting cll-1

Also Published As

Publication number Publication date
JP2020522573A (ja) 2020-07-30
RU2019143638A3 (es) 2022-02-10
EP3634994A1 (en) 2020-04-15
US20220169741A1 (en) 2022-06-02
EP3634994A4 (en) 2021-06-30
CA3065447A1 (en) 2018-12-13
US20190031764A1 (en) 2019-01-31
JP7268011B2 (ja) 2023-05-02
KR20200014385A (ko) 2020-02-10
KR102661320B1 (ko) 2024-05-03
AU2018279278A1 (en) 2019-12-19
CN110959012A (zh) 2020-04-03
US11192951B2 (en) 2021-12-07
BR112019025612A2 (pt) 2020-06-16
KR20240056666A (ko) 2024-04-30
RU2019143638A (ru) 2021-07-09
WO2018224950A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
EP4249068A3 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
MX2019002946A (es) Anticuerpos anti-pd-1 y sus usos.
MX2022012189A (es) Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas.
SG11201806511XA (en) Device and method for bonding substrates
SG10201807877TA (en) Hybrid immunoglobulin containing non-peptidyl linkage
WO2018064307A3 (en) Low-viscosity antigen binding proteins and methods of making them
MX2017004001A (es) Humanizacion de anticuerpos a base de angulo de interdominio de cadena pesada-cadena ligera (vh-vl).
PH12017502213A1 (en) Compositions and methods for treating celiac sprue disease
MX2019014572A (es) Métodos de ingeniería de carga superficial para la producción de anticuerpos biespecíficos.
EA202190136A1 (ru) Способ очистки антигена
MX2023014077A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
EP3674313A4 (en) NEW POLYPEPTIDE AND IMP PRODUCTION PROCESS USING IT
PH12016500403A1 (en) An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof
WO2016089968A3 (en) Thermoreversible hydrogels from the arrested phase separation of elastin-like polypeptides
MX2018014966A (es) Peptidos monolipidados resistentes a proteasas.
SG11201908543WA (en) Anti-pd-l1 antibody for detecting pd-l1
MX2021016066A (es) Anticuerpos heterodimericos que se unen a cd38 y cd3.
EP3741774A4 (en) N-TERMINAL FUSION PARTNER FOR THE MANUFACTURING OF A RECOMBINANT POLYPEPTID AND PROCESS FOR THE MANUFACTURING OF A RECOMBINANT POLYPEPTID USING THESE
WO2019094669A3 (en) Self-assembling protein structures and components thereof
WO2019130241A8 (es) Mezcla de biocontroladores fúngicos para el control de hongos causales del brazo muerto de la vid
MX2019005552A (es) Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.
WO2020127354A3 (en) Polypeptides
WO2019103512A3 (ko) 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질
TW202430563A (zh) 抗cd38抗體及其使用方法